Trial · NCT07440381
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
NCT07440381, Phase 3, Not yet recruiting, Heart Care Foundation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE. Trials, record NCT07440381. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07440381
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
- NCT number
- NCT07440381
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 600 participants, estimated
- Lead sponsor
- Heart Care Foundation
- Conditions
- Acute Coronary Syndromes, Secondary Prevention, Lipids
- Interventions
- Triple oral lipid lowering treatment
- First posted
- 2026-02-27
- Last updated
- 2026-02-27
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean percent change in LDL-c levels | 8 weeks | the difference in the mean percent change in LDL-c levels from baseline at 8 weeks between triple combo therapy and usual care. |
| Secondary | Percentage of patients with LDL-c level <70 mg/dL | 8 weeks | Difference in percentage of patients with LDL-c level \<70 mg/dL at 8 weeks |
| Secondary | Percentage of patients with LDL-c level <55 mg/dL | 8 weeks | Difference in percentage of patients with LDL-c level \<55 mg/dL at 8 weeks |
| Secondary | Percentage of patients with LDL-c level <40 mg/dL in those with a recurrent ACS event in the previous 48 months | 8 weeks | Difference in percentage of patients with LDL-c level \<40 mg/dL at 8 weeks in those with a recurrent ACS event in the previous 48 months |
| Secondary | Change in high-sensitivity CRP (hs-CRP) | 8 weeks | Change in high-sensitivity CRP (hs-CRP) at 8 weeks |
| Secondary | Persistence of active treatment and discontinuation rate | 8 weeks | Rate of persistence of active treatment and discontinuation rate of allocated treatment |
| Secondary | Rate of adverse events | 8 weeks | Safety of the investigational study drug by adverse event recording |
| Secondary | Rate of adverse events | 3 months | Safety of the investigational study drug by adverse event recording |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07440381
GET https://conductscience.org/api/trials/v1/NCT07440381/registered